PET-CT for response assessment and treatment adaptation in head and neck cancer

The Lancet Oncology

Volumn 11, Issue 7, 2010, Pages 661-669

  Bussink, J ^a   van Herpen, C M L ^a   Kaanders, J H A M ^a   Oyen, W J G ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

1 FLUORO 3 (2 NITRO 1 IMIDAZOLYL) 2 PROPANOL F 18; 3' FLUOROTHYMIDINE F 18; CETUXIMAB; CISPLATIN; FLUORODEOXYGLUCOSE F 18; METHIONINE C 11; NIMORAZOLE; NITROIMIDAZOLE DERIVATIVE; PIMONIDAZOLE; TIRAPAZAMINE;

CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; DISTANT METASTASIS; HEAD AND NECK CANCER; HUMAN; HYPOXIA; INTENSITY MODULATED RADIATION THERAPY; LYMPH NODE METASTASIS; MOLECULAR IMAGING; NECK DISSECTION; NONHUMAN; ORGAN PRESERVATION; OROPHARYNX CARCINOMA; PATIENT SELECTION; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; RADIATION DOSE DISTRIBUTION; REVIEW; SENSITIVITY AND SPECIFICITY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SQUAMOUS CELL CARCINOMA; TREATMENT FAILURE; TREATMENT PLANNING; TREATMENT RESPONSE; TUMOR VOLUME;

CARCINOMA, SQUAMOUS CELL; DRUG MONITORING; HEAD AND NECK NEOPLASMS; HUMANS; NEOPLASM, RESIDUAL; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; RADIOPHARMACEUTICALS; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; TOMOGRAPHY, X-RAY COMPUTED;

EID: 77954029167     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(09)70353-5     Document Type: Review

References (76)

1. Argiris A, Karamouzis MV, Raben D, Ferris RL Head and neck cancer. Lancet 2008, 371:1695-1709.
2. Ljungkvist AS, Bussink J, Kaanders JH, Wiedenmann NE, Vlasman R, van der Kogel AJ Dynamics of hypoxia, proliferation and apoptosis after irradiation in a murine tumor model. Radiat Res 2006, 165:326-336.
3. Withers HR, Taylor JM, Maciejewski B The hazard of accelerated tumor clonogen repopulation during radiotherapy. Acta Oncol 1988, 27:131-146.
4. Bourhis J, Overgaard J, Audry H, et al. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 2006, 368:843-854. on behalf of the Meta-Analysis of Radiotherapy in Carcinomas of Head and neck (MARCH) Collaborative Group.
5. Nordsmark M, Bentzen SM, Rudat V, et al. Prognostic value of tumor oxygenation in 397 head and neck tumors after primary radiation therapy. An international multi-center study. Radiother Oncol 2005, 77:18-24.
6. Overgaard J Hypoxic radiosensitization: adored and ignored. J Clin Oncol 2007, 25:4066-4074.
7. Overgaard J, Hansen HS, Overgaard M, et al. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. Radiother Oncol 1998, 46:135-146.
8. Kaanders JH, Bussink J, van der Kogel AJ ARCON: a novel biology-based approach in radiotherapy. Lancet Oncol 2002, 3:728-737.
9. Rischin D, Peters LJ, O'Sullivan B, et al. Phase III study of tirapazamine, cisplatin and radiation versus cisplatin and radiation for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 2008, 26(suppl). LBA6008 (abstr).
10. Pignon JP, le Maître A, Maillard E, Bourhis J Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009, 92:4-14. on behalf of the MACH-NC Collaborative Group.
11. Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006, 354:567-578.
12. Buck AK, Schirrmeister H, Hetzel M, et al. B3-deoxy-3-[(18)F]fluorothymidine-positron emission tomography for noninvasive assessment of proliferation in pulmonary nodules. Cancer Res 2002, 62:3331-3334.
13. 18F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res 2004, 10:2245-2252.
14. Van de Wiele C, Lahorte C, Oyen W, et al. Nuclear medicine imaging to predict response to radiotherapy: a review. Int J Radiat Oncol Biol Phys 2003, 55:5-15.
15. 18F]-2-fluoro-2-deoxy-D-glucose positron emission tomography in patients with locally advanced non-small-cell lung cancer. J Clin Oncol 2005, 23:8362-8370.
16. Porter JR Louis Pasteur; achievements and disappointments, 1861. Bacteriol Rev 1961, 25:389-403.
17. Warburg O On respiratory impairment in cancer cells. Science 1956, 124:269-270.
18. Busk M, Horsman MR, Jakobsen S, Bussink J, van der Kogel A, Overgaard J Cellular uptake of PET tracers of glucose metabolism and hypoxia and their linkage. Eur J Nucl Med Mol Imaging 2008, 35:2294-2303.
19. 18F-misonidazole PET in non-small cell lung cancer and head and neck cancer before radiotherapy. J Nucl Med 2005, 46:253-260.
20. 2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models. Int J Radiat Oncol Biol Phys 2005, 61:1493-1502.
21. 18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group Study 98.02. J Clin Oncol 2006, 24:2098-2104.
22. Grosu AL, Souvatzoglou M, Röper B, et al. Hypoxia imaging with FAZA-PET and theoretical considerations with regard to dose painting for individualization of radiotherapy in patients with head and neck cancer. Int J Radiat Oncol Biol Phys 2007, 69:541-551.
23. Ljungkvist AS, Bussink J, Kaanders JH, et al. Hypoxic cell turnover in different solid tumor lines. Int J Radiat Oncol Biol Phys 2005, 62:1157-1168.
24. 18F]-FMISO PET data to analyse tumour hypoxia. Phys Med Biol 2005, 50:2209-2224.
25. 18F-fluoroazomycin arabinoside. J Nucl Med 2005, 4:106-113.
26. 18F-fluoromisonidazole in head and neck cancer. Int J Radiat Oncol Biol Phys 2008, 70:235-242.
27. 18F-FMISO positron emission tomography. Int J Radiat Oncol Biol Phys 2008, 70:1219-1228.
28. Rasey JS, Grierson JR, Wiens LW, Kolb PD, Schwartz JL Validation of FLT uptake as a measure of thymidine kinase-1 activity in A549 carcinoma cells. J Nucl Med 2002, 43:1210-1217.
29. 18F-3'-deoxy-3'-fluorothymidine measurements using positron emission tomography. Eur J Nucl Med Mol Imaging 2009, 36:389-395.
30. 18F-FDG uptake on PET with Ki-67 immunohistochemistry in non-small cell lung cancer. Eur J Nucl Med Mol Imaging 2007, 34:1610-1616.
31. 18F]FLT PET for diagnosis and staging of thoracic tumours. Eur J Nucl Med Mol Imaging 2003, 30:1407-1412.
32. 18F-FLT PET does not discriminate between reactive and metastatic lymph nodes in primary head and neck cancer patients. J Nucl Med 2007, 48:726-735.
33. 11C-methionine PET, correlation with morphologic response, and clinical outcome. J Nucl Med 2003, 44:526-532.
34. 18F-FDG PET and CT in patients with head and neck cancer. J Nucl Med 2006, 47:256-261.
35. Belhocine T, Steinmetz N, Hustinx R, et al. Increased uptake of the apoptosis-imaging agent 99mTc recombinant human annexin V in human tumors after one course of chemotherapy as a predictor of tumor response and patient prognosis. Clin Cancer Res 2002, 8:2766-2774.
36. Blankenberg FG In vivo detection of apoptosis. J Nucl Med 2008, 49:81S-95S.
37. Niu G, Cai W, Chen K, Chen X Non-invasive PET imaging of EGFR degradation induced by a heat shock protein 90 inhibitor. Mol Imaging Biol 2008, 10:99-106.
38. 89Zr-labeled cetuximab uptake assessed with PET. J Nucl Med 2009, 50:123-131.
39. 11C-PD153035 in humans. J Nucl Med 2009, 50:303-308.
40. Levashova Z, Backer MV, Horng G, Felsher D, Backer JM, Blankenberg FG SPECT and PET imaging of EGF receptors with site-specifically labeled EGF and dimeric EGF. Bioconjug Chem 2009, 20:742-749.
41. 18F]FMISO autoradiography and pimonidazole [corrected] immunohistochemistry in human head and neck carcinoma xenografts. Eur J Nucl Med Mol Imaging 2008, 35:1803-1811.
42. Bussink J, Kaanders JHAM, van der Kogel AJ Tumor hypoxia at the micro regional level: clinical relevance and predictive value of exogenous and endogenous hypoxic cell markers. Radiother Oncol 2003, 67:3-15.
43. 18F-FDG PET in oncology. J Nucl Med 2008, 49:480-508.
44. Rodrigues RS, Bozza FA, Christian PE, et al. Comparison of whole-body PET/CT, dedicated high-resolution head and neck PET/CT, and contrast-enhanced CT in preoperative staging of clinically M0 squamous cell carcinoma of the head and neck. J Nucl Med 2009, 50:1205-1213.
45. 18F-FDG uptake in reactive neck lymph nodes of oral cancer: relationship to lymphoid follicles. J Nucl Med 2008, 49:1053-1059.
46. 18F-fluorodeoxyglucose positron emission tomography to evaluate cervical node metastases in patients with head and neck squamous cell carcinoma: a meta-analysis. J Natl Cancer Inst 2008, 100:712-720.
47. Daisne JF, Duprez T, Weynand B, et al. Tumor volume in pharyngolaryngeal squamous cell carcinoma: comparison at CT, MR imaging, and FDG PET and validation with surgical specimen. Radiology 2004, 233:93-100.
48. 18F-fluoro-deoxy-glucose-positron emission tomography-based target volume definition in head and neck cancer. Int J Radiat Oncol Biol Phys 2007, 69:1282-1289.
49. Grégoire V, Bol A, Geets X, Lee J Is PET-based treatment planning the new standard in modern radiotherapy? The head and neck paradigm. Semin Radiat Oncol 2006, 16:232-238.
50. Bentzen SM Theragnostic imaging for radiation oncology: dose-painting by numbers. Lancet Oncol 2005, 6:112-117.
51. Madani I, Duthoy W, Derie C, et al. Positron emission tomography-guided, focal-dose escalation using intensity-modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys 2007, 68:126-135.
52. Grégoire V, Haustermans K, Geets X, Roels S, Lonneux M PET-based treatment planning in radiotherapy: a new standard?. J Nucl Med 2007, 48:68S-77S.
53. Geets X, Tomsej M, Lee JA, et al. Adaptive biological image-guided IMRT with anatomic and functional imaging in pharyngo-laryngeal tumors: impact on target volume delineation and dose distribution using helical tomotherapy. Radiother Oncol 2007, 85:105-115.
54. 18F-fluoromisonidazole PET, diffusion-weighted MRI, and dynamic contrast-enhanced MRI. J Nucl Med 2009, 50:1020-1027.
55. 18F]-misonidazole positron emission tomography for head-and-neck cancer patients undergoing concurrent chemoradiotherapy. Int J Radiat Oncol Biol Phys 2009, 75:101-118.
56. Christian N, Lee JA, Bol A, De Bast M, Jordan B, Grégoire V The limitation of PET imaging for biological adaptive-IMRT assessed in animal models. Radiother Oncol 2009, 91:101-116.
57. Kaanders JH, Wijffels KI, Marres HA, et al. Pimonidazole binding and tumor vascularity predict for treatment outcome in head and neck cancer. Cancer Res 2002, 62:7066-7074.
58. 18F-FLT) in head and neck cancer patients before and early after initiation of chemoradiation therapy. J Nucl Med 2009, 50:1028-1035.
59. Troost EG, Bussink J, Hoffmann AL, Boerman OC, Oyen WJG, Kaanders JHAM. 18FLT-PET-CT for early response monitoring and dose escalation in oropharyngeal tumors. J Nucl Med (in press).
60. Bussink J, Kaanders JH, van der Kogel AJ Microenvironmental transformations by VEGF- and EGF-receptor inhibition and potential implications for responsiveness to radiotherapy. Radiother Oncol 2007, 82:10-17.
61. Bussink J, van der Kogel AJ, Kaanders JH Activation of the PI3-K/AKT pathway and implications for radioresistance mechanisms in head and neck cancer. Lancet Oncol 2008, 9:288-296.
62. Lammering G, Hewit TH, Valerie K, et al. Modulation of intratumoral hypoxia by the epidermal growth factor receptor inhibitor gefitinib detected using small animal PET imaging. Mol Cancer Ther 2005, 4:1417-1422.
63. Manning HC, Merchant NB, Foutch AC, et al. Molecular imaging of therapeutic response to epidermal growth factor receptor blockade in colorectal cancer. Clin Cancer Res 2008, 14:7413-7422.
64. Greven KM, Williams DW, McGuirt WF, et al. Serial positron emission tomography scans following radiation therapy of patients with head and neck cancer. Head Neck 2001, 23:942-946.
65. Isles MG, McConkey C, Mehanna HM A systematic review and meta-analysis of the role of positron emission tomography in the follow up of head and neck squamous cell carcinoma following radiotherapy or chemoradiotherapy. Clin Otolaryngol 2008, 33:210-222.
66. 11C]methionine. Int J Radiat Oncol Biol Phys 1995, 32:787-794.
67. Lowe VJ, Dunphy FR, Varvares M, et al. Evaluation of chemotherapy response in patients with advanced head and neck cancer using [F-18]fluorodeoxyglucose positron emission tomography. Head Neck 1997, 19:666-674.
68. 17Ga scintigraphy) in assessment of combined intraarterial chemotherapy and radiotherapy for head and neck carcinoma. J Nucl Med 2003, 44:198-206.
69. Passero VA, Branstetter BF, Heron DE, et al. How to best assess tumor response after curative chemoradiotherapy (CRT) for head and neck squamous cell carcinomas (HNSCC): RECIST or PET/CT?. J Clin Oncol 2008, 26(suppl):6023. (abstr).
70. Lavertu P, Adelstein DJ, Saxton JP, et al. Management of the neck in a randomized trial comparing concurrent chemotherapy and radiotherapy with radiotherapy alone in resectable stage III and IV squamous cell head and neck cancer. Head Neck 1997, 19:559-566.
71. 18F-FDG PET in managing the neck in node-positive head and neck cancer after chemoradiotherapy. Acta Otolaryngol 2008, 7:1-7.
72. Tan A, Adelstein DJ, Rybicki LA, et al. Ability of positron emission tomography to detect residual neck node disease in patients with head and neck squamous cell carcinoma after definitive chemoradiotherapy. Arch Otolaryngol Head Neck Surg 2007, 133:435-440.
73. Velázquez RA, McGuff HS, Sycamore D, Miller FR The role of computed tomographic scans in the management of the N-positive neck in head and neck squamous cell carcinoma after chemoradiotherapy. Arch Otolaryngol Head Neck Surg 2004, 130:74-77.
74. 18F-FDG PET/CT in assessing the neck after concurrent chemoradiotherapy for locoregional advanced head and neck cancer. J Nucl Med 2008, 49:532-540.
75. Porceddu SV, Jarmolowski E, Hicks RJ, et al. Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo)radiotherapy in head and neck cancer. Head Neck 2005, 27:175-181.
76. Yao M, Smith RB, Graham MM, et al. The role of FDG PET in management of neck metastasis from head-and-neck cancer after definitive radiation treatment. Int J Radiat Oncol Biol Phys 2005, 63:991-999.